Acute effects of methcathinone and manganese in mice: A dose response study. by Asser, Andres et al.
Heliyon 5 (2019) e02475Contents lists available at ScienceDirect
Heliyon
journal homepage: www.heliyon.comAcute effects of methcathinone and manganese in mice: A dose
response study
Andres Asser a, Sulev K~oks b, Ursel Soomets c, Anton Terasmaa d, Martin Sauk g, Mall Eltermaa e,
Piret Piip a, Kumari Ubhayasekera f, Jonas Bergquist f, Pille Taba a,*
a Department of Neurology and Neurosurgery, University of Tartu, Puusepa 8, Tartu, 51014, Estonia
b Perron Institute for Neurological and Translational Science, University of Western Australia, Perth, WA, Australia
c Department of Biochemistry, University of Tartu, Ravila 19, Tartu, 50411, Estonia
d Department of Physiology, University of Tartu, Ravila 19, Tartu, 50411, Estonia
e Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 19, Tartu, 50411, Estonia
f Department of Chemistry, Biomedical Center, Uppsala University, SE-751 24, Uppsala, Sweden
g Institute of Molecular and Cell Biology, University of Tartu, Riia 23, Tartu, 51010, EstoniaA R T I C L E I N F O
Keywords:
Neuroscience
Toxicology
Behavioral neuroscience
Dose-response relationship
Nervous system
Neurotoxicology
Ephedrone
Toxic parkinsonism
Manganese
Methcathinone* Corresponding author.
E-mail address: pille.taba@kliinikum.ee (P. Taba
https://doi.org/10.1016/j.heliyon.2019.e02475
Received 29 November 2018; Received in revised f
2405-8440/© 2019 The Authors. Published by Else
nc-nd/4.0/).A B S T R A C T
An intravenously injectable illicit drug made by mixing pseudoephedrine, potassium permanganate, vinegar and
water, yielding methcathinone (Mcat) and manganese (Mn), induces an extrapyramidal syndrome with parkin-
sonism, dystonia, gait and balance disorders similar to manganism. Although the cause of the syndrome is largely
attributed to Mn, the interaction of the drug's individual components is not known and the role of Mcat is possibly
underestimated. Aim of the present study was to analyze dose-dependent behavioral effects of the mixture and its
two main active components Mcat and Mn in an acute setting and determine the lethal doses of each substance.
Three groups of C57BL/6 mice were injected intraperitoneally with (1) the drug mixture containing 10, 25, 50,
100 or 150 mg of Mcat and respectively 1.6, 3.8, 6.9, 17.1 and 22.6 mg of Mn per kilogram of body weight; (2) 10,
25, 50, 100, 150, 200 or 300 mg of racemic Mcat/kg of body weight; (3) MnCl2 10, 25 or 50 mg/kg of body
weight. Locomotor activity of the animals, various signs and time of death were recorded.
Lower doses (10 and 25 mg/kg) of Mcat had a clear motor activity stimulating effect and this was clearly dose-
dependent. High doses of Mcat produced epileptic seizures in 74% of the animals and became lethal with the
highest doses. Similarly, the mixture had a clear dose-dependent stimulating effect and the higher doses became
lethal. The LD50 of the pseudoephedrine mixture was 110.2 mg of Mcat/kg and for pure Mcat 201.7 mg/kg. Mn
did not prove to be lethal in doses up to 50 mg/kg, but had a strong dose dependent inhibitory effect on the
animals’ behavior. Our data reveal that both Mn and Mcat have a signiﬁcant role in the toxicity of the mixture.1. Introduction
During the last 20 years, a drug induced extrapyramidal syndrome
has been described mostly in Eastern European countries [1, 2] with
cases also reported in North America andWestern European countries [3,
4]. Although not very widespread, it has a devastating effect on the social
and physical functioning of its sufferers.
The clinical syndrome is caused by an illicit drug composition made
by adding potassium permanganate and vinegar to common cold rem-
edies containing pseudoephedrine. The drug is then injected intrave-
nously multiple times a day, generating an immediate short-lasting
amphetamine-like “high” driving further abuse of the mixture. After).
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versible extrapyramidal syndrome described by marked hypokinesia,
dysarthria, dystonia and postural instability with early falls. This syn-
drome closely resembles manganism - a neurological condition caused by
excessive environmental exposure to manganese (Mn) [5]. Despite
evident symptoms of extrapyramidal damage, the syndrome, like man-
ganism, does not respond to usual antiparkinsonian treatment and re-
mains a lifelong cause of disability to the vast majority of the inﬂuenced
population.
As a byproduct of the chemical reaction, the mixture contains a large
amount of two potent neurotoxic substances –methcathinone (Mcat) and
Mn. Due to the similarities between manganism and the aforementionedSeptember 2019
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mentally abundant metal is known to accumulate in the basal ganglia
leading to signiﬁcant damage of several monoaminergic systems and
harming basal ganglia function [6]. During active drug use the subjects
have an increased blood concentration of manganese as well as T1
hyperintense lesions of the basal ganglia visible on magnetic resonance
imaging. Both of these alterations will normalize after cessation of drug
use while the clinical syndrome remains unchanged [2].
Mcat (also named as ephedrone) is a drug from the amphetamine
class of substances. It can be synthesized by oxidizing ephedrine or
pseudoephedrine with potassium permanganate under acidic conditions.
The reduction product of these substances is methamphetamine (METH)
[7]. Mcat has a dose and enantiomer dependent dopamine depleting
effect in the striatum (STR) of rodents [8], as well as several other dele-
terious effects on different neurotransmitter systems. There is increasing
evidence suggesting an increased risk for movement disorders associated
with psychostimulant use [9].
Presently there is a lack of literature concerning the Mcat/Mnmixture
to serve as the basis for further preclinical studies. Thus the aim of this
study was to determine and describe the acute dose related effects (lethal
doses, motor behavior) of the mixture and its main components in mice
in order to establish an animal model of the neurological syndrome in
future studies.
2. Materials and methods
This study was approved by the National Board of Animal Experi-
ments of Estonian Ministry of Agriculture, permission number 124,
04.12.2008. Funding for the study was provided by grant PUT1239 from
the Estonian Research Council.
2.1. Animals
Male C57BL/6 mice (Harlan Laboratories B.V., Venray, The
Netherlands), aged four months, were housed in groups of 6 in plastic
housing containers with open tops. The animals were kept in vivarium
conditions (constant room temperature and humidity) on a 12 h light/
dark cycle with free access to water and food. The animals received a
standard laboratory animal feed (R-70, LabFor, Sweden). This feed has a
manganese (Mn) content of 68 mg/kg of feed. The health status, cage
bedding and nutrition were checked once per day. Prior to injections, the
mice were weighed and randomly assigned into treatment groups of 14
animals each.
2.2. Drugs and dose-response curve
The methcathinone and manganese containing mixture (Mcat/Mn)
was prepared as follows: 48 pills of Sudafed (GlaxoSmithKlineTable 1
Concentrations of substances according to groups.
Mcat/Mn Meth
Group Methcathinone concentration
(mg/kg)
Manganese concentration (mg/
kg)
Grou
Control 0 0 Cont
Mcat/Mn
1
10 1.6 Mcat
Mcat/Mn
2
25 3.8 Mcat
Mcat/Mn
3
50 6.9 Mcat
Mcat/Mn
4
100 17.1 Mcat
Mcat/Mn
5
150 22.6 Mcat
Mcat
Mcat
2Pharmaceuticals, Poznan, Poland) containing a total of 2880 mg of
pseudoephedrine hydrochloride ([(þ)-(1S,2S)-2-methylamino-1-phe-
nylpropan-1-ol, C10H15NO, CAS 90-82-4, MW 165.22]) were stripped of
the coating layer, mixed with 4.8 ml (96 drops) of vinegar ([30% acetic
acid, C2H4O2], AS JAPS M.V.M., Estonia) and 4 grams of potassium
permanganate (KMnO4, UAB “Valentis”, Vilnius, Lithuania) and were
then added to 88 ml of boiling tap water. The mixture was stirred until
the uncoated pills were dissolved and then cooled rapidly in a cold water
bath. The clear top layer was ﬁltered through a ﬁlter paper to remove any
visible debris.
Mcat content of the solution was measured (see below) and the
resulting solution was further diluted with 0.9% saline (Sodium Chloride
0.9%, B. Braun Melsungen AG, Melsungen, Germany) in order to deliver
10, 25, 50, 100 and 150 mg of Mcat per kilogram of animal body weight
(groups Mcat/Mn 1 – Mcat/Mn 5, see Table 1). The Mn content of each
dilution was measured by atomic absorption spectrometry (see below).
This method of drug preparation closely resembles the one used by ad-
dicts [1].
Racemic Mcat ([(RS)-2-(methylamino)-1-phenylpropan-1-one hy-
drochloride, C10H13NOHCl, MW199.68], Sigma-Aldrich Corp., St. Louis,
MO, USA) was dissolved in sterile 0.9% saline (Sodium Chloride 0.9%, B.
Braun Melsungen AG, Melsungen, Germany) in order to deliver 10, 25,
50, 100, 150, 200 and 300 mg of Mcat per kilogram of animal body
weight (groups Mcat 1 – Mcat 7, Table 1).
Manganese chloride (MnCl2 x 4H2O, Sigma-Aldrich Corp., St. Louis,
MO, USA) was diluted with sterile 0.9% saline in order to deliver either
10, 25 or 50mg of MnCl2 per kilogram of animal body weight (groupsMn
1- Mn 3, Table 1).
All control groups received sterile 0.9% saline.
All injections were given intraperitoneally with a 0.3 ml injection
volume. For the purposes of easier comparison to Mcat, Mcat/Mn groups
are labelled according to the amount of Mcat in the mixture. All doses are
listed in Table 1.
After completion of all necessary experimental work the animals were
euthanized. Animals were euthanized using an intraperitoneal injection
of Sodium Thiopenthal (300 mg/kg). When death of the animal was
conﬁrmed, the brain was removed and ﬂash-frozen in liquid nitrogen and
then stored at -80C for any further studies.
2.3. Motor activity recording
Locomotor activity was tested immediately after the injections during
a 30 min period in photoelectric motility boxes. Each box measuring 448
 448  450 mm was connected to a computer (ActiMot/MoTil, TSE
Technical & Scientiﬁc Equipment GmbH, Germany). Illumination of the
boxes was approximately 400 lux. Each animal was placed in the center
area of the box singly and time in locomotion (in seconds), distance
travelled (in meters), time on rear feet (in seconds) and time spent in thecathinone (Mcat) Manganese (Mn)
p Methcathinone concentration
(mg/kg)
Group Manganese concentration (mg/
kg)
rol 0 Control 0
1 10 Mn 1 10
2 25 Mn 2 25
3 50 Mn 3 50
4 100
5 150
6 200
7 300
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deﬁned as 60% of the centermost ﬂoor area. Seizures, stereotypical
behavior and time of death were recorded manually during the 30 min
period.
2.4. Methcathinone content analysis
Mcat content of the non diluted Mcat/Mn solution was analyzed. The
Acquity UPC2 system from Waters Corporation, Milford, USA, was
equipped with a binary solvent delivery pump, an autosampler, a column
oven and a back pressure regulator. The qualitative analysis was per-
formed at 40C using an Acquity UPC2 HSS C18 SB column (100 mm 
3.0 mm, 1.8 μm; Waters, Milford, MA, USA). The mobile phase ﬂow rate
was maintained at 2.0 mL/min with a gradient elution (eluent A, CO2;
eluent B, methanol with 0.1% formic acid). The gradient program was
started with 2% of component B, then, a linear gradient was programmed
from 2% to 50% for 1.00 min, held for 0.20 min followed by a linear
gradient down to 2% B in 0.30 min, and ﬁnally it was held for 1.50 min
which allowed ionic liquids to elute out from the instrument. Isocratic
solvent was ethanol at a ﬂow rate of 0.3 mL/min. The back pressure was
set at 1900 psi and the injection volume was 1.0 μL.
Mcat was identiﬁed by using a Waters Xevo TQ-S mass spectrometer
(Milford, MA, USA). The data acquisition was in the positive ion elec-
trospray ionization (ESI) mode. The desolvation gas was nitrogen, and
the collision gas was argon (0.25 mL/min). The data acquisition range
was m/z 25–575. The capillary voltage was 1.0 kV, the cone voltage was
32.0 V, and the source offset was 58 V. The source temperature was 150
C and the desolvation temperature was 550 C with the desolvation gas
ﬂow rate of 600.0 L/h. The cone gas ﬂow was 150.0 L/h. The nebulizer
gas ﬂow was at 4.9 bar. MS data were collected using two separate scan
functions. The ﬁrst scan function was set at low collision energy (5 eV),
which provided parent ions, and the second scan function was set at high
collision energy (12 eV) which provided fragment ions (m/z 145.88) of
parent ions (m/z 164.08) (multiple reactions monitoring (MRM)) from
standard Mcat purchased from Sigma AB (Stockholm, Sweden). The
dwell time for each function was set at 0.08 s. Data were acquired and
analyzed with Waters MassLynx v4.1 software. Identiﬁcation was done
by comparing retention time and standard fragments obtained from an
authentic Mcat. Finally the quantiﬁcation was accomplished using an
external calibration curve. The sample analysis was performed in tripli-
cates to test the repeatability, and the results are acceptable. All data
collected in centroid mode were obtained using Masslynx NT4.1 software
(Waters Corp., Milford, MA USA).
2.5. Mn content analysis
Mn levels in the Mcat/Mn samples were determined by electro-
thermal atomic absorption spectrometry (ETAAS) as described by Truus
et al. [31] Spectra AA 220Z atomic absorption spectrometer (Varian,
Mulgrave, Australia) equipped with a side-heated GTA-110Z graphite
atomizer, a Zeeman-effect background correction, and an integrated
autosampler was used. Graphite tubes with coating and platforms made
of pyrolytic graphite were used. Argon of 99.998% purity (AGA, Helsinki,
Finland) was used as the purge gas. The stock atomic spectroscopy
standard solution (1000 mg/L1) of Mn was gradually diluted with 4%
HNO3 before use. Water was puriﬁed to 18.2 MΩ cm1 resistivity using a
Milli-Q water puriﬁcation system (Millipore, Bedford, USA). The total
volume of the solution pipetted into the atomizer was 0.2 mL (0.1 mL of
the sample solution plus 0.1 mL of the modiﬁer solution). At least two
replicates were measured for each solution.
2.6. Statistical analysis
For the survival analysis we used the groups with lethal outcomes.
Survival proportions for these groups were calculated using the Kaplan-
Meier method with log rank test for curve comparison. LD50 values3were calculated from the dose response data using a sigmoidal dose-
response curve and three parameter logistic regression analysis.
Motility data was analyzed using one-way analysis of variance with
Dunnett's test for groups comparison and prior D'Agostino and Pearson
normality test with the cutoff p value of 0.05. All toxin groups were
compared to the control group. P value of <0.05 was considered statis-
tically signiﬁcant. Analysis was carried out using Prism 6 software
(GraphPad Software Inc., LaJolla, CA, USA).
3. Results
3.1. Dose-dependent effects
TheMcat concentration in the non dilutedMcat/Mnmixture was 2.64
 0.02 mg/ml. Mn concentration in the various dilutions of Mcat/Mn
solution is shown in Table 1.
Main locomotor results are reported by substance in Figs. 1, 2, and 3.
In general, all substances had a dose dependent effect on the motor ac-
tivity of the animals. Mcat and Mcat/Mn had a strong stimulating effect
at lower doses (groups Mcat 25 mg/kg, Mcat 50 mg/kg and Mcat/Mn 25
mg/kg and 50 mg/kg), causing a signiﬁcant increase in motor activity.
Behavior altering effects of all active substances were evident within the
ﬁrst 5 min of the injection. The highest doses of all substances resulted in
signiﬁcant decrease of motor activity as well as exploratory behavior of
the animals. At the same time the intermediate doses had no signiﬁcant
effect on motor activity. High doses of Mn resulted in signiﬁcantly
decreased motor activity (Figs. 3A and 3B).
All injected substances also inﬂuenced exploratory behavior of the
animals. Mcat/Mn had the most profound and consistent effect on the
time the animals spent in the center of the box and on rear feet. The effect
of Mcat was less uniform. Mn had a signiﬁcant effect on exploratory
behavior only at the highest doses.
3.2. Survival analysis
Higher doses of Mcat and Mcat/Mn were lethal. Mortality after
administration of 100 mg/kg of Mcat/Mn was 35.7% (5/14) and after
150 mg/kg it was 92.9% (13/14). Injection of 200 and 300 mg/kg of
Mcat was lethal in 57.1% (8/14) and 100% (14/14) of the cases
respectively. One animal died after administration of 100 mg/kg of Mcat
(Fig. 4). Calculated LD50 for Mcat/Mn was 110.2 mg/kg and for Mcat it
was 201.7 mg/kg. Mn was not lethal at doses up to 50 mg/kg.
3.3. Behavioral analysis
Seizure activity and stereotypical movements were recorded. Mcat
had the strongest epileptogenic effect. Most animals in groups Mcat 150
mg/kg (7/14, 50%), Mcat 200mg/kg (11/14, 78%) andMcat 300mg/kg
(13/14, 93%) developed generalized tonic-clonic seizures within a few
minutes after the injection. With Mcat/Mn, seizures occurred in all ani-
mals with lethal outcome in groups Mcat/Mn 100 mg/kg (13/14, 92.9%)
and Mcat/Mn 150 mg/kg (5/14, 35.7%). Injections of Mn were not
epileptogenic throughout the dose range.
Stereotypical behavior included repetitive movements with front legs
and continuous attempts to chew the box ﬂoor. This kind of behavior was
mostly observed in group Mcat 100 mg/kg (10/14, 71%) but also in
group Mcat 150 mg/kg (4/14, 29%). With the higher doses, all animals
developed marked difﬁculties of movement.
High doses of Mn (group Mn 50 mg/kg) did not provoke any seizures
or stereotypical behaviour. Instead, these animals (14/14, 100%) were
incapable of moving around for a mean duration of 22.7 min after the
injection. This effect was considerably less pronounced with lower doses.
4. Discussion
With this study we demonstrate the acute effects of a “home made”
Fig. 1. Effects of Mcat/Mn on time in motion (A) and number of rearings (B) grouped by methcathinone dose. Presented values are means with 95% conﬁdence
interval. * signiﬁes p < 0.05 and ** signiﬁes p < 0.01. The 150 mg/kg group has been excluded from the analysis and in the 100 mg/kg group only the surviving
animals were included.
Fig. 2. Effect of Mcat on time in motion (A) and number of rearings (B). Values presented are means with 95% conﬁdence interval. * is p < 0.05 and ** is p < 0.01.
The 300 mg/kg group has been excluded from analysis and in the 200 mg/kg group only the surviving animals were included in the analysis.
Fig. 3. Effect of Mn on time in motion (A) and number of rearings (B). The values presented are means with 95% conﬁdence interval, all groups are compared to the
control group. * is p < 0.05 and ** is p < 0.01.
A. Asser et al. Heliyon 5 (2019) e02475narcotic mixture containing Mcat and Mn as the main active components
and compare it to the effects of the two components separately.
Both, Mn and Mcat are potent neurotoxic substances. Mn toxicity
continues to be a widely researched topic in part due to its apparent
association with an irreversible extrapyramidal syndrome (see the
excellent review by O'Neal and Zheng [10]). Mn is an essential element
for normal cellular functioning. If administered in excessive doses, it
accumulates in mitochondria and leads to cellular damage in the basal4ganglia with the main target areas being substantia nigra, striatum and
globus pallidus [11]. Uptake of Mn is mediated largely by divalent metal
transporter 1 (DMT1), which is widely expressed in striatum, substantia
nigra pars reticulata and less in globus pallidus and substantia nigra pars
compacta [12]. Although mechanisms of Mn toxicity are not precisely
known, the key components are shown to be the production of reactive
oxygen species (ROS), induction of mitochondrial dysfunction [13],
protein aggregation [14] and interference with neurotransmitter levels
Fig. 4. Survival curves after administration of Mcat/Mn (A) and Mcat (B). In both groups comparison of survival curves with logrank test shows signiﬁcant difference
between curves (p < 0.0001).
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sensitive compared to other neurotransmitters. Mn toxicity is dependent
on its oxidation state, with Mn3þ being a more potent toxin than Mn2þ
[16].
The role of Mn in the toxic properties of the Mcat/Mn is stressed by
the fact that when during preparation potassium permanganate is
substituted with sodium dichromate, sulfuric acid, acetone or toluene,
the drug users avoid the extrapyramidal syndrome [17]. Several exper-
iments have found that in rodents chronic low-level manganese exposure
is associated with impaired motor function already at doses below 10
mg/kg [18]. A study by Yang et al. [19] shows that intrastriatal admin-
istration of MnCl2 also has an acute effect on locomotor activity of mice.
We were able to conﬁrm that a single dose of MnCl2 signiﬁcantly impairs
locomotor and exploratory activity of mice. 50 mg/kg of Mn exceeds the
amount of Mn given as part of the Mcat/Mn mixture and was not lehtal.
Data from literature has shown that cumulative Mn doses of up to 5300
mg/kg can be tolerated.
We observed a dose dependent effect of racemic Mcat and Mcat/Mn
containing S(-)methcathinone on the locomotor activity of mice. Racemic
Mcat has a strong stimulating effect at 10 mg/kg, whereas equivalent
stimulating effect is reached at 25 mg/kg of Mcat as part of the mixture. A
notable difference in lethal doses between Mcat (200 mg/kg) and Mcat/
Mn (150 mg/kg of Mcat) is observed. The reason for this phenomenon is
unclear. A previous study by Gatch et al [20] has shown similar results
with Mcat, although a lehtal dose was not reached. Increased locomotor
activity of animals has also been shown in a study by Anneken et al [30],
where doses of racemic Mcat up to 80 mg/kg increased both movement
time as well as stereotypy time. Mcat belongs to the phenylisopropyl-
amines group of substances. It is the N-monomethylated derivate of
cathinone. It can be easily synthesized by oxidizing pseudoephedrine
with potassium permanganate. In rats racemic Mcat demonstrates more
potent activity in stimulus generalization tests compared to racemic
cathinone or amphetamine and also induces release of radioactivity form
[3H]dopamine prelabeled caudate tissue similar to amphetamine and
METH [21]. Two stereoisomers of Mcat are available. Structure activity
relationship studies have shown S(-)methcathinone to be more potent
than R(þ)methcathinone as a locomotor stimulant with the racemic
compound ﬁtting between the two [22].
Amphetamines are known to deplete striatal dopamine [23] and
damage dopaminergic nerve terminals [24]. In addition, serotonin
(5-HT) levels and 5-HT transporter density are decreased in METH
abusers. Although analogy of the structure-activity relationship between
Mcat and N-monomethylated amphetamine derivates exists, they are not
completely identical [25]. Psychostimulants are neurotoxic towards the
dopaminergic system. A PET study by McCann et al. [26] shows reduced
striatal binding of a highly speciﬁc dopamine transporter (DAT) ligand
[11C]WIN-35,428 in abstinent Mcat users – a feature similar to subjects
suffering from Parkinson's disease (PD). Additional common pathological
changes shared by psychostimulant abuse and PD have been identiﬁed.5These include METH induced cytoplasmic inclusions in substantia nigra
pars compacta neurons, inhibition of the ubiquitin-proteasome system
due to faulty signalling cascades [27], involvement of speciﬁc G-protein
coupled receptor (GPCR) signaling mediator proteins like β-arrestin [28]
and several others [29].
As a shortcoming of the study, the data does not give a clear under-
standing about the reasons why the drugs were lethal. We did not mea-
sure the cardiovascular effects or alterations in body temperature, which
could both signiﬁcantly alter survival after Mcat use. Effects at the
cellular level were also not studied at this time. Mice were selected due to
the fact that they have been proven to be an effective and informative
model system as demonstrated by numerous studies concerning move-
ment disorders. This model allows for assessment of behavioural effects
as well as structural changes in brain tissue, although the results can not
necessarily be directly related to humans.
Although in previous studies the toxicity of Mcat/Mn was justiﬁed
solely by the presence of Mn, our study supports a pivotal role of Mcat in
the mixture. This is further supported by the aforementioned ﬁndings
from several studies. Mcat is the drug with clear psychostimulating ac-
tivity and has a relatively small activity window – doses 10 times higher
than the most effective dose become lethal. We conclude that general
toxicity of Mcat may be present already at lower doses and therefore we
can not exclude cytotoxicity of the most active dose. Characterisation of
the cytotoxic properties of Mcat and Mcat/Mn is already the scope of
further studies. Current results also provide information for dose selec-
tion in further studies.
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